PLGA from PolySciTech used in development of Improved broad-spectrum influenza A vaccine

 

Researchers at Indian Institute of Science, Centers for Disease Control and Prevention, Nitte University, and Mynvax Private Limited used PLGA (Cat# AP041 https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP041#h) from PolySciTech division of Akina, Inc. as part of development of a particle delivery-adjuvent system for influenza A vaccine. This research holds promise to prevent common causes of flu. Read more: Yadav, Rajesh T., Mansi Sharma, Santhosh K. Nagaraj, Rohan Narayan, Abinaya Kaliappan, Uma Shanmugasundaram, Rahul Chavan et al. "Broad protection against Influenza A Viruses via an adjuvant-free mucosal microparticle vaccine with conserved CD8/CD4 bispecific peptides." bioRxiv (2026): 2026-03. https://www.biorxiv.org/content/10.64898/2026.03.29.715080.abstract

“Influenza A viruses (IAVs) cause substantial global morbidity and mortality and are responsible for most known viral pandemics. Their rapid antigenic evolution enables escape from natural and vaccine-induced immunity, requiring annual vaccine reformulation, which offers limited breadth and variable effectiveness. Although a universal influenza vaccine remains a critical objective, most strategies have focused on conserved viral glycoproteins to elicit broadly neutralizing antibodies, with comparatively fewer efforts targeting conserved T cell antigens to achieve cross-subtype protection. Current T cell-based approaches often rely on individual CD8+ epitopes, which are limited by peptide instability, delivery constraints, and dependence on adjuvants. Here, we demonstrate a T cell-focused vaccine strategy that uses evolutionary consensus of IAV M1 and NP from the H1N1 and H3N2 subtypes to predict, map, and screen conserved regions enriched with multiple CD8+ and CD4+ epitopes. We selected the top-performing peptides from immunogenicity screening. We encapsulated them in polylactic-co-glycolic acid microparticles (PLGA-MPs) engineered for selective uptake by APCs and pH-dependent sustained release. Intranasal delivery of this vaccine formulation targeted the primary site of infection and induced robust mucosal immunity without the need for conventional adjuvants. Both human and murine influenza-experienced T cells mounted potent recall responses to the vaccine. In mice, immunization elicited strong CD8+ and CD4+ T cell responses and conferred broad protection against homologous H1N1 and H3N2 as well as heterologous H5N1 IAV subtypes. These findings collectively establish a mucosal, T cell-based vaccine platform that is adjuvant-free and capable of providing broad protection against IAV and other viruses with pandemic potential.”

Benchtop to Bedside clinical manufacturing with MidWestGMP https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Distributed Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Distributed Polymer Products: https://akinainc.com/polyscitech/products/ashland/

PrecisionGelTM from Vivos https://akinainc.com/polyscitech/products/vivos/